BIOMAT Database Logo BIOMAT Database Logo

Intrahepatic expression of c-fos, c-myb and c-myc oncogenes: correlation with virus-induced chronic liver disease and response to interferon. 1997

G Tappero, and M Farina, and F Negro, and G Anfossi, and L Mattiello, and P D Giuli, and P Colombatto, and M R Brunetto, and A Angeli, and F Bonino
Department of Internal Medicine, University of Turin, S. Luigi Hospital, Orbassano, Italy.

OBJECTIVE Oncogenes were activated in experimental models of hepatocyte regeneration. We studied the intrahepatic expression of c-fos, c-myb and c-myc protooncogenes in 117 patients with chronic liver disease: 12 with hepatitis B, 15 HBsAg carriers, 73 with hepatitis C and 17 with non-viral liver damage. METHODS Oncoproteins were detected by indirect immunofluorescence using high affinity and monoclonal antibodies. Grade and stage of liver damage were measured by numerical score. RESULTS Nuclear c-fos and/or c-myb were found in 7 (58.3%) hepatitis B patients, in 38 (52%) hepatitis C patients, in 1 (6.6%) HBsAg carrier (p < 0.004) and in none of the non-viral disease patients (p < 0.0001). In no case was c-myc detected. Oncoproteins were correlated with the histological activity index (p < 0.0001) and its components: lobular degeneration and periportal necrosis (p < 0.0001), fibrosis (p < 0.005) and portal inflammation (p < 0.03). Thirty-one chronic hepatitis C patients were treated with alpha-IFN: 9 out of 14 oncoprotein-positive patients (64%) were non-responders, 5 (36%) relapsed and none was a sustained responder. Conversely 9 out of 17 (53%) oncoprotein-negative patients, including 3 patients with histologically active cirrhosis, showed long-term response (p < 0.005). CONCLUSIONS Intrahepatic c-fos and c-myb were detected in chronic viral hepatitis patients, but not in non-viral liver diseases. Their expression correlated with the grade and stage of liver disease and with poor response to alpha-IFN.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D005455 Fluorescent Antibody Technique Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (FLUORESCENT ANTIBODY TECHNIQUE, DIRECT) or an indirect method, by formation of antigen-antibody complex which is then labeled with fluorescein-conjugated anti-immunoglobulin antibody (FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT). The tissue is then examined by fluorescence microscopy. Antinuclear Antibody Test, Fluorescent,Coon's Technique,Fluorescent Antinuclear Antibody Test,Fluorescent Protein Tracing,Immunofluorescence Technique,Coon's Technic,Fluorescent Antibody Technic,Immunofluorescence,Immunofluorescence Technic,Antibody Technic, Fluorescent,Antibody Technics, Fluorescent,Antibody Technique, Fluorescent,Antibody Techniques, Fluorescent,Coon Technic,Coon Technique,Coons Technic,Coons Technique,Fluorescent Antibody Technics,Fluorescent Antibody Techniques,Fluorescent Protein Tracings,Immunofluorescence Technics,Immunofluorescence Techniques,Protein Tracing, Fluorescent,Protein Tracings, Fluorescent,Technic, Coon's,Technic, Fluorescent Antibody,Technic, Immunofluorescence,Technics, Fluorescent Antibody,Technics, Immunofluorescence,Technique, Coon's,Technique, Fluorescent Antibody,Technique, Immunofluorescence,Techniques, Fluorescent Antibody,Techniques, Immunofluorescence,Tracing, Fluorescent Protein,Tracings, Fluorescent Protein
D006521 Hepatitis, Chronic INFLAMMATION of the LIVER with ongoing hepatocellular injury for 6 months or more, characterized by NECROSIS of HEPATOCYTES and inflammatory cell (LEUKOCYTES) infiltration. Chronic hepatitis can be caused by viruses, medications, autoimmune diseases, and other unknown factors. Chronic Hepatitis,Cryptogenic Chronic Hepatitis,Hepatitis, Chronic, Cryptogenic,Hepatitis, Chronic Active,Hepatitis, Chronic Persistent,Chronic Active Hepatitis,Chronic Hepatitis, Cryptogenic,Chronic Persistent Hepatitides,Chronic Persistent Hepatitis,Hepatitis, Cryptogenic Chronic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D015682 Retroviridae Proteins, Oncogenic Retroviral proteins that have the ability to transform cells. They can induce sarcomas, leukemias, lymphomas, and mammary carcinomas. Not all retroviral proteins are oncogenic. Oncogenic Retroviridae Proteins,Proteins, Oncogenic Retroviridae
D015870 Gene Expression The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION. Expression, Gene,Expressions, Gene,Gene Expressions

Related Publications

G Tappero, and M Farina, and F Negro, and G Anfossi, and L Mattiello, and P D Giuli, and P Colombatto, and M R Brunetto, and A Angeli, and F Bonino
Oncogenes with potential nuclear function: myc, myb and fos.
January 1986, Cancer surveys,
G Tappero, and M Farina, and F Negro, and G Anfossi, and L Mattiello, and P D Giuli, and P Colombatto, and M R Brunetto, and A Angeli, and F Bonino
Expression of c-fos, c-myb, and c-myc in human monocytes: correlation with monocytic differentiation.
May 1987, Blood,
G Tappero, and M Farina, and F Negro, and G Anfossi, and L Mattiello, and P D Giuli, and P Colombatto, and M R Brunetto, and A Angeli, and F Bonino
Regulation of the proto-oncogenes c-sis, c-fos, c-myc and c-myb in acute myeloid leukemias.
January 1992, Neoplasma,
G Tappero, and M Farina, and F Negro, and G Anfossi, and L Mattiello, and P D Giuli, and P Colombatto, and M R Brunetto, and A Angeli, and F Bonino
Regulated expression of the c-myb and c-myc oncogenes during erythroid differentiation.
January 1986, Journal of cellular biochemistry,
G Tappero, and M Farina, and F Negro, and G Anfossi, and L Mattiello, and P D Giuli, and P Colombatto, and M R Brunetto, and A Angeli, and F Bonino
c-myc, c-fos, and c-myb gene expression in human pituitary adenomas.
July 1994, The Journal of clinical endocrinology and metabolism,
G Tappero, and M Farina, and F Negro, and G Anfossi, and L Mattiello, and P D Giuli, and P Colombatto, and M R Brunetto, and A Angeli, and F Bonino
Expression of c-fos and c-myc proto-oncogenes in human adrenal pheochromocytomas.
February 1990, The Journal of clinical endocrinology and metabolism,
G Tappero, and M Farina, and F Negro, and G Anfossi, and L Mattiello, and P D Giuli, and P Colombatto, and M R Brunetto, and A Angeli, and F Bonino
Expression of myb, myc and fos proto-oncogenes during the differentiation of a murine myeloid leukaemia.
January 1984, Nature,
G Tappero, and M Farina, and F Negro, and G Anfossi, and L Mattiello, and P D Giuli, and P Colombatto, and M R Brunetto, and A Angeli, and F Bonino
Structure and expression of c-myc and c-fos proto-oncogenes in thyroid carcinomas.
January 1988, British journal of cancer,
G Tappero, and M Farina, and F Negro, and G Anfossi, and L Mattiello, and P D Giuli, and P Colombatto, and M R Brunetto, and A Angeli, and F Bonino
Intrahepatic expression of hepatitis C virus antigens in chronic liver disease.
January 1995, The Journal of pathology,
G Tappero, and M Farina, and F Negro, and G Anfossi, and L Mattiello, and P D Giuli, and P Colombatto, and M R Brunetto, and A Angeli, and F Bonino
Treatment of murine peritoneal macrophages with bacterial lipopolysaccharide alters expression of c-fos and c-myc oncogenes.
October 1986, Journal of immunology (Baltimore, Md. : 1950),
Copied contents to your clipboard!